Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 06 Jun 2023 According to trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology, as of Feb 2023, 26 participants have been accrued.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 17 Jan 2021 Planned number of patients changed from 88 to 78, as per Trial design presented at the 2021 Gastrointestinal Cancers Symposium